Aclaris Therapeutics (ACRS) Competitors $1.57 -0.02 (-1.26%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.59 +0.02 (+1.27%) As of 07/11/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRS vs. PHAT, RLAY, ABUS, TNGX, CDXC, DNTH, MENS, MGTX, UPB, and XNCRShould you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Phathom Pharmaceuticals (PHAT), Relay Therapeutics (RLAY), Arbutus Biopharma (ABUS), Tango Therapeutics (TNGX), ChromaDex (CDXC), Dianthus Therapeutics (DNTH), Jyong Biotech (MENS), MeiraGTx (MGTX), Upstream Bio (UPB), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry. Aclaris Therapeutics vs. Its Competitors Phathom Pharmaceuticals Relay Therapeutics Arbutus Biopharma Tango Therapeutics ChromaDex Dianthus Therapeutics Jyong Biotech MeiraGTx Upstream Bio Xencor Phathom Pharmaceuticals (NASDAQ:PHAT) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation. Is PHAT or ACRS more profitable? Phathom Pharmaceuticals has a net margin of -422.42% compared to Aclaris Therapeutics' net margin of -732.42%. Phathom Pharmaceuticals' return on equity of 0.00% beat Aclaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals-422.42% N/A -90.11% Aclaris Therapeutics -732.42%-30.73%-22.74% Which has higher valuation & earnings, PHAT or ACRS? Aclaris Therapeutics has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhathom Pharmaceuticals$55.25M11.60-$334.33M-$5.24-1.75Aclaris Therapeutics$18.72M9.08-$132.07M-$1.39-1.13 Which has more volatility & risk, PHAT or ACRS? Phathom Pharmaceuticals has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Do analysts prefer PHAT or ACRS? Phathom Pharmaceuticals currently has a consensus target price of $17.50, indicating a potential upside of 90.63%. Aclaris Therapeutics has a consensus target price of $8.71, indicating a potential upside of 455.05%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than Phathom Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Does the media prefer PHAT or ACRS? In the previous week, Aclaris Therapeutics had 3 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 5 mentions for Aclaris Therapeutics and 2 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 0.94 beat Aclaris Therapeutics' score of 0.85 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in PHAT or ACRS? 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 23.0% of Phathom Pharmaceuticals shares are held by company insiders. Comparatively, 6.4% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryPhathom Pharmaceuticals and Aclaris Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRS vs. The Competition Export to ExcelMetricAclaris TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$172.17M$2.45B$5.61B$9.11BDividend YieldN/A1.79%5.24%4.01%P/E Ratio-1.139.4227.9620.25Price / Sales9.08729.02430.8999.65Price / CashN/A165.3637.4658.16Price / Book1.094.608.045.49Net Income-$132.07M$31.26M$3.18B$250.27M7 Day Performance8.65%4.80%3.67%4.80%1 Month Performance2.61%5.42%4.09%7.68%1 Year Performance18.94%-4.36%29.58%16.36% Aclaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRSAclaris Therapeutics2.2156 of 5 stars$1.57-1.3%$8.71+455.1%+24.6%$172.17M$18.72M-1.13100Analyst ForecastPHATPhathom Pharmaceuticals4.2031 of 5 stars$8.66-2.9%$17.50+102.1%-18.9%$622.74M$55.25M-1.65110RLAYRelay Therapeutics2.3321 of 5 stars$3.55-2.2%$17.67+397.7%-53.6%$622.34M$10.01M-1.59330News CoveragePositive NewsInsider TradeABUSArbutus Biopharma2.2916 of 5 stars$3.14-3.1%$5.50+75.2%-9.7%$620.55M$6.17M-7.6690Positive NewsTNGXTango Therapeutics1.6516 of 5 stars$5.43-4.7%$12.20+124.7%-38.3%$617.85M$40.99M-4.4590Positive NewsCDXCChromaDex3.1155 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120DNTHDianthus Therapeutics1.541 of 5 stars$18.25-3.2%$53.00+190.4%-30.8%$606.22M$6.24M-6.3480Positive NewsMENSJyong BiotechN/A$7.81-1.6%N/AN/A$603.66MN/A0.0031Positive NewsGap UpHigh Trading VolumeMGTXMeiraGTx4.2489 of 5 stars$7.74+3.1%$24.00+210.1%+85.3%$603.54M$33.28M-3.34300News CoverageInsider TradeUPBUpstream Bio1.9494 of 5 stars$10.98-2.0%$56.50+414.6%N/A$602.49M$2.37M0.0038XNCRXencor4.5141 of 5 stars$7.94-5.7%$28.00+252.6%-54.5%$599.26M$110.49M-2.59280News Coverage Related Companies and Tools Related Companies Phathom Pharmaceuticals Competitors Relay Therapeutics Competitors Arbutus Biopharma Competitors Tango Therapeutics Competitors ChromaDex Competitors Dianthus Therapeutics Competitors Jyong Biotech Competitors MeiraGTx Competitors Upstream Bio Competitors Xencor Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRS) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored"I'm risking my reputation on this"Most people think you need thousands to profit from crypto. But this free book exposes how even small inves...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
